[go: up one dir, main page]

BRPI0910439B8 - derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos - Google Patents

derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos

Info

Publication number
BRPI0910439B8
BRPI0910439B8 BRPI0910439A BRPI0910439A BRPI0910439B8 BR PI0910439 B8 BRPI0910439 B8 BR PI0910439B8 BR PI0910439 A BRPI0910439 A BR PI0910439A BR PI0910439 A BRPI0910439 A BR PI0910439A BR PI0910439 B8 BRPI0910439 B8 BR PI0910439B8
Authority
BR
Brazil
Prior art keywords
ampk
activators
protein kinase
activated protein
medicines
Prior art date
Application number
BRPI0910439A
Other languages
English (en)
Inventor
Charon Christine
Cravo Daniel
Lepifre Franck
Hallakou-Bozec Sophie
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0910439A2 publication Critical patent/BRPI0910439A2/pt
Publication of BRPI0910439B1 publication Critical patent/BRPI0910439B1/pt
Publication of BRPI0910439B8 publication Critical patent/BRPI0910439B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk). a presente invenção refere-se aos compostos de fórmula (i) em que r1, r2 e r3 são como definidos na reivindicação 1, incluindo composições farmacêuticas das mesmas e para o seu uso no tratamento e/ou na prevenção de doenças e distúrbios modulados pelo agonistas de amp. a invenção é também dirigida aos intermediários e a um método de preparação dos compostos de fórmula (i).
BRPI0910439A 2008-04-11 2009-03-17 derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos BRPI0910439B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP082903642 2008-04-11
EP08290364 2008-04-11
PCT/EP2009/001937 WO2009124636A1 (en) 2008-04-11 2009-03-17 Thienopyridone derivatives as amp-activated protein kinase (ampk) activators

Publications (3)

Publication Number Publication Date
BRPI0910439A2 BRPI0910439A2 (pt) 2015-09-29
BRPI0910439B1 BRPI0910439B1 (pt) 2020-10-20
BRPI0910439B8 true BRPI0910439B8 (pt) 2021-05-25

Family

ID=40671017

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910439A BRPI0910439B8 (pt) 2008-04-11 2009-03-17 derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos

Country Status (25)

Country Link
US (1) US8563729B2 (pt)
EP (1) EP2262500B1 (pt)
JP (1) JP5592348B2 (pt)
KR (1) KR101630466B1 (pt)
CN (1) CN101998853B (pt)
AU (1) AU2009235784B2 (pt)
BR (1) BRPI0910439B8 (pt)
CA (1) CA2721025C (pt)
CO (1) CO6300954A2 (pt)
DK (1) DK2262500T3 (pt)
EA (1) EA017756B1 (pt)
EC (1) ECSP10010599A (pt)
ES (1) ES2584278T3 (pt)
HR (1) HRP20160907T1 (pt)
HU (1) HUE027857T2 (pt)
IL (1) IL208067A (pt)
MX (1) MX2010011047A (pt)
MY (1) MY155836A (pt)
NZ (1) NZ589136A (pt)
PL (1) PL2262500T3 (pt)
PT (1) PT2262500T (pt)
SI (1) SI2262500T1 (pt)
UA (1) UA103321C2 (pt)
WO (1) WO2009124636A1 (pt)
ZA (1) ZA201008050B (pt)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010011916A (es) * 2008-05-05 2010-11-26 Merck Patent Gmbh Derivados de tienopiridonas como activadores de proteinas cinasa activados por amp (ampk).
PL2519527T3 (pl) 2009-12-29 2014-06-30 Poxel Tieno[2,3-B]Pirydynodionowe aktywatory AMPK i ich zastosowanie terapeutyczne
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2552435A1 (en) 2010-04-02 2013-02-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions comprising ampk activator (metformin/troglitazone) for the treatment of myotonic dystrophy type 1 (dm1)
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CA2809492C (en) 2010-09-01 2018-12-18 Bayer Cropscience Ag Herbicidally active ketosultams and diketopyridines
EP2683690A1 (en) * 2011-03-07 2014-01-15 GlaxoSmithKline LLC Quinolinone derivatives
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
EP2679591A1 (en) * 2012-06-29 2014-01-01 Poxel Thienopyridone derivatives useful as activators of AMPK
JP6064062B2 (ja) 2013-03-15 2017-01-18 ファイザー・インク Ａｍｐｋを活性化させるインダゾール化合物
WO2015002818A1 (en) 2013-07-01 2015-01-08 Emory University Treating or preventing nephrogenic diabetes insipidus
EP3089748A4 (en) 2014-01-02 2017-09-27 Massachusetts Eye & Ear Infirmary Treating ocular neovascularization
CN105037322A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环和烷氧苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892568A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和腈基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104945369A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 一种含六甲基苯环和硝基苯结构的黄原酸酯类化合物、其制备方法及用途
CN104892569A (zh) * 2015-06-23 2015-09-09 佛山市赛维斯医药科技有限公司 末端取代的硝苯六甲苯黄原酸酯类的化合物、制备方法及用途
CN105037321A (zh) * 2015-06-23 2015-11-11 佛山市赛维斯医药科技有限公司 含六甲基苯环的黄原酸酯类的ampk激活剂、制备方法及用途
CN104945370A (zh) * 2015-06-23 2015-09-30 佛山市赛维斯医药科技有限公司 含卤代噻吩和硝苯六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945372A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含二硝基以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104945371A (zh) * 2015-06-24 2015-09-30 佛山市赛维斯医药科技有限公司 一种含腈基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
CN104926755A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 硝苯双酰基苄胺类ampk激活剂、其制备方法及用途
CN104926756A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 一类含腈基苯的双酰基苄胺类化合物、其制备方法及用途
CN105001181A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一类双酰基苄胺类的ampk激活剂、其制备方法及用途
CN105037296A (zh) * 2015-06-24 2015-11-11 佛山市赛维斯医药科技有限公司 一类卤代苯双酰基苄胺类的ampk激活剂、其制备方法及用途
CN104926757A (zh) * 2015-06-24 2015-09-23 佛山市赛维斯医药科技有限公司 含烷氧苯基的双酰基苄胺类ampk激活剂、其制备方法及用途
CN105001194A (zh) * 2015-06-24 2015-10-28 佛山市赛维斯医药科技有限公司 一种含氨基噻吩以及六甲苯结构的黄原酸酯类化合物、制备方法及用途
RS61919B1 (sr) * 2015-06-25 2021-06-30 Univ Health Network Inhibitori hpk1 i postupci za njihovo korišćenje
WO2017055925A2 (en) 2015-09-30 2017-04-06 Instituto De Medicina Molecular Methods for attenuating parasite virulence
EP3478297A1 (en) 2016-06-30 2019-05-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of cardiomyopathies
AU2019379797B2 (en) * 2018-11-16 2024-06-27 Poxel Monohydrate potassium salt of a thienopyridone derivative and its preparation process
WO2020201263A1 (en) 2019-04-01 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of cardiac remodeling
US11850238B2 (en) * 2020-03-26 2023-12-26 Poxel Use of a thienopyridone derivative in the treatment of adrenoleukodystrophy or adrenomyeloneuropathy
MX2022012350A (es) * 2020-04-02 2022-10-27 Poxel Uso de un derivado de tienopiridona en el tratamiento de poliquistosis renal autosomica dominante (adpkd).
JP2023526625A (ja) 2020-05-19 2023-06-22 キャリーオペ，インク． Ａｍｐｋアクチベーター
JP2023531726A (ja) 2020-06-26 2023-07-25 キャリーオペ，インク． Ａｍｐｋアクチベーター
CN116322663A (zh) 2020-09-30 2023-06-23 比奥维拉迪维治疗股份有限公司 Ampk激活剂及其使用方法
WO2022106892A1 (en) 2020-11-17 2022-05-27 Instituto De Medicina Molecular Anti-malarial compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU626418B2 (en) 1989-05-16 1992-07-30 Merrell Pharmaceuticals Inc. Excitatory amino acid antagonists
DE4444815A1 (de) * 1994-12-15 1996-06-20 Merck Patent Gmbh Thienopyridone
GB0214268D0 (en) * 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
US7119205B2 (en) * 2003-05-16 2006-10-10 Abbott Laboratories Thienopyridones as AMPK activators for the treatment of diabetes and obesity
EP1754483A1 (en) * 2005-08-18 2007-02-21 Merck Sante Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
AU2009212462B2 (en) 2008-02-04 2012-09-13 Mercury Therapeutics, Inc. AMPK modulators

Also Published As

Publication number Publication date
CN101998853B (zh) 2015-02-11
IL208067A (en) 2015-05-31
HUE027857T2 (en) 2016-11-28
EP2262500A1 (en) 2010-12-22
WO2009124636A1 (en) 2009-10-15
NZ589136A (en) 2012-06-29
CA2721025C (en) 2016-07-26
EA017756B1 (ru) 2013-02-28
PL2262500T3 (pl) 2016-09-30
SI2262500T1 (sl) 2016-09-30
KR20100137563A (ko) 2010-12-30
AU2009235784B2 (en) 2013-09-19
HRP20160907T1 (hr) 2016-09-23
ECSP10010599A (es) 2010-12-30
ES2584278T3 (es) 2016-09-26
HK1155955A1 (en) 2012-06-01
JP2011516510A (ja) 2011-05-26
CO6300954A2 (es) 2011-07-21
CN101998853A (zh) 2011-03-30
BRPI0910439A2 (pt) 2015-09-29
IL208067A0 (en) 2010-12-30
EP2262500B1 (en) 2016-04-27
DK2262500T3 (en) 2016-08-15
MX2010011047A (es) 2010-10-26
AU2009235784A1 (en) 2009-10-15
KR101630466B1 (ko) 2016-06-14
UA103321C2 (ru) 2013-10-10
US20110034505A1 (en) 2011-02-10
BRPI0910439B1 (pt) 2020-10-20
EA201001585A1 (ru) 2011-06-30
US8563729B2 (en) 2013-10-22
PT2262500T (pt) 2016-08-16
JP5592348B2 (ja) 2014-09-17
MY155836A (en) 2015-12-15
CA2721025A1 (en) 2009-10-15
ZA201008050B (en) 2011-07-27

Similar Documents

Publication Publication Date Title
BRPI0910439B8 (pt) derivados de tienopiridona como ativadores da proteína quinase ativada por amp (ampk), seu processo de preparação, e medicamentos
BRPI0910832B8 (pt) derivados de tienopiridona como ativadores de proteína quinase ativada por amp (ampk), seus usos, seu processo de preparação e seus intermediários, e medicamentos.
BRPI0709680B8 (pt) derivados de pirrol, tiofeno e furano substituídos por piridil e piridimil como inibidores de quinase
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BRPI0918750B8 (pt) derivado de 2-carboxamida cicloamino ureia, seu uso e sua composição farmacêutica
BR112022001324A2 (pt) Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BRPI0513086A (pt) 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos
BRPI0919873B8 (pt) compostos de pirazol[1,5-a]pirimidina substituídos como inibidores da trk quinase, seus processos de preparação e composições farmacêuticas
BRPI0613570B8 (pt) composto, composição farmacêutica e uso de um composto ou um sal farmaceuticamente aceitável do mesmo
BRPI0818533B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para a preparação de um composto
BR112013018515A2 (pt) derivados de pirrol tricíclico, processo para preparação e seu uso como inibidores da quinase
BR112014014184A2 (pt) triazolopiridinas substituídas e seu uso como inibidores de ttk
BR112013023517A2 (pt) "inibidores de produção de leucotrieno, seus usos, e composição farmacêutica"
BR112013001088A2 (pt) "derivados substituídos como inibidores a quinase de imidazoquinolina"
UY32848A (es) Compuestos heterocíclicos de oxima
BRPI0821115A8 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0610850A2 (pt) derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados
BRPI0717367B8 (pt) di-hidropirazolonas substituídas, seus usos e seu processo de preparação, e medicamento
BR112012015916A2 (pt) derivados de pirazina e seu uso no tratamento de distúrbios neurológicos
BR112015020772A2 (pt) compostos de pirimidina e piridina e seu uso
BRPI0714553B8 (pt) derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso
BR112015002118A2 (pt) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
BR112012003464B8 (pt) compostos de piranil aril metil benzoquinaozlinona, uso dos mesmos, e, composição farmacêutica
BRPI0806400A8 (pt) composto, composição farmacêutica, produtos, usos de pelo menos um composto, método in vitro, kit, ligantes e processo de preparação de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 20/10/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2822 DE 04-02-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.